Aripiprazole
- PDF / 151,318 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 163 Views
1 S
Severe idiosyncratic reaction manifested as severe hyperglycaemia: case report An 18-year-old woman developed severe idiosyncratic reaction manifested as severe hyperglycaemia during treatment with aripiprazole for suicidal ideation, ideas of reference, persecutory delusions and paranoia. The woman was admitted after she presented with suicidal ideation, ideas of reference, persecutory delusions and paranoia. She had type 1 diabetes which was well controlled before the admission. For the first 9 days of hospitalisation, her blood sugars were within the normal range. She was started on oral aripiprazole 10mg every morning to control suicidal ideation, ideas of reference, persecutory delusions and paranoia. Within 9 hours of aripiprazole initiation, her blood sugar level was found to be significantly increased. The woman’s aripiprazole treatment was stopped after 5 days due to an inability to adequately control blood glucose. Diabetic ketoacidosis and pancreatitis were ruled out as laboratory results showed normal ketones, amylase and lipase. Blood sugar monitoring device malfunction (Accu-Chek Inform II monitor and Freestyle Libra device) was excluded as a cause. Diet and insulin administration techniques were closely monitored by the nursing staff. Endocrinology and clinical dietary services were consulted. Despite an increase in her daily insulin, her blood sugars were as high as 25.9 mmol/L. Her blood sugar and insulin requirements remained elevated over the following 17 days. Thereafter, her blood sugar levels gradually decreased and normalised. Dick M, et al. Significant, prolonged hyperglycemia in an 18-year-old type 1 diabetic patient post initiation of aripiprazole: A case report. Schizophrenia Bulletin 46 (Suppl. 803503016 1): S231-S232 (plus poster) abstr. T3, Jul 2020. Available from: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234022/ [abstract]
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
